All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

d Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise ⭐️significant different of PD signal in PsA group ⭐️5 non-PsA pts still had PD🤔 Would be interesting to further classify differences in PD intensity… Abs#POS1058 #EULAR2021 @RheumNow https://t.co/SLhqq4wgCl
Robert B Chao, MD doctorRBC ( View Tweet)
#Polypharmacy of meds not related to RA ⬇️remission & more adverse events but not if adjusting for comorbidities- so many diagnoses with RA ⬇️outcomes only defined as >1 drug #EULAR2021 @RheumNow OP0098 https://t.co/lMazBDTPw1
Janet Pope Janetbirdope ( View Tweet)
#OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted @RheumNow #EULAR2021 https://t.co/mwHJwIhRVE
Paul Studenic Stiddyo ( View Tweet)
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Paul Studenic Stiddyo ( View Tweet)
BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares https://t.co/dUJMKFkZ52 https://t.co/oAgKcGbW0k

Links:

Andy Vermaut AndyVermaut ( View Tweet)
#Eular2021 OP0289: ⭐️Remission off-Rx: SLEDAI=0 (minus serol), no IS ⭐️Remission on-Rx: SLEDAI 0, Pred<5mg, maintenance IS ⭐️LDAS: SLEDAI<=2 wo pred or IS ⭐️LLDAS: SLEDAI <=4, no maj organ, no new features, pred <=7.5+main These states have ⬇️ damage accrual, rec'd T2T @Rhuemnow

Eric Dein ejdein1 ( View Tweet)

My toe hurts & it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbidities to worse outcomes if CRF in gout. HTN⬆️ Gout has SNIPs assoc w HTN & May be the cause. Incident Gout assoc with Acute coronary syndrome OP0193 OP0192 #EULAR2021 @RheumNow @eular_org https://t.co/CS6o0T1FL2
Janet Pope Janetbirdope ( View Tweet)
#EULAR2021 OP0290: Cluster analysis of APLS 4 Clusters: ⭐️ 2ndary APS, non-criteria ⭐️ ♂️ with CV risks ⭐️OB morbidity ⭐️Isolated LA + @RheumNow

Eric Dein ejdein1 ( View Tweet)

A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay #EULAR2021 Dr. Jonathan Kay reviews three RA abstracts from the opening plenary session at the EULAR 2021 virtual meeting: abstract OP0012; abstract OP0007; and abstract OP0006. https://t.co/6GhSLXqysd https://t.co/h2k00GzHE5

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA pts cycle through more advanced therapies! Kind of obvious but in N=363, 9.4% with advanced Rx were difficult to treat vs 39% if > 1 ts\bDMARDs. Worse pts had ⬆️disease duration. Drug resistance over time? POS0405 @RheumNow #EULAR2021 @eular_org

Janet Pope Janetbirdope ( View Tweet)

Imagine being top expert for 37 years. World RENOWNED, won 🏅’s. Then there’s a crisis, IN YOUR FIELD, & as you step up, you’re degraded at every turn by a con man. Yet you carry on your duty cuz 🇺🇸 depends on it. THAT’S professionalism. THAT’S Dr Fauci https://t.co/DkVyfAQHsp
🇵🇱Reality Dose🇺🇸 LRPow79 ( View Tweet)
Stop #smoking! Smoking is not good for you & others! 👉🏽Passive smoking exposures during childhood & adulthood associated with increased risk of #RheumatoidArthritis Could favour citrullination in genetically proned people By @YannNgyn OP0012 #EULAR2021 #rheumatoid https://t.co/ImDR0aLAXd
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Several domains of disease in #PsA need to be considered. Composite scores have the benefit of providing a summary. What is your favourite composite score for PsA in your clinical practice? #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

Blindness with Tocilizumab in GCA: Is it a Worry? Dr. David Liew ( @drdavidliew ) #EULAR2021 https://t.co/xokPqGMEyA https://t.co/NJ3PrFR6nF

Links:

Dr. John Cush RheumNow ( View Tweet)

After 1st JAKi in RA would you use a 2nd #Jaki? @eular_org

Janet Pope Janetbirdope ( View Tweet)

Given the data on poorer pregnancy outcomes in higher disease activity in RA in Abstr#OP0210, should we alter our current management approach? @RheumNow #EULAR2021

Richard Conway RichardPAConway ( View Tweet)

The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021 https://t.co/S0ownscRKv https://t.co/PJODe0U6wr

Links:

Dr. John Cush RheumNow ( View Tweet)
"The concept of JAK selectivity is based on in vitro assays, with limited impact on cellular and clinical aspecrts of the use of JAK inhibitors" - Hendrik Schulze-Koops, @LMU_Muenchen #EULAR2021 @RheumNow

David Liew drdavidliew ( View Tweet)

×